B-intervention	0	10	Lumpectomy
I-intervention	11	15	plus
I-intervention	16	25	tamoxifen
I-intervention	26	28	or
I-intervention	29	40	anastrozole
I-intervention	41	45	with
I-intervention	46	48	or
I-intervention	49	56	without
I-intervention	57	62	whole
I-intervention	63	69	breast
I-intervention	70	81	irradiation
O	82	84	in
B-eligibility	85	90	women
I-eligibility	91	95	with
I-eligibility	96	105	favorable
I-eligibility	106	111	early
I-eligibility	112	118	breast
I-eligibility	119	125	cancer
O	125	126	.

O	127	129	In
O	130	135	women
O	136	140	with
O	141	150	favorable
O	151	156	early
O	157	163	breast
O	164	170	cancer
O	171	178	treated
O	179	181	by
O	182	192	lumpectomy
O	193	197	plus
O	198	207	tamoxifen
O	208	210	or
O	211	222	anastrazole
O	222	223	,
O	224	226	it
O	227	234	remains
O	235	242	unclear
O	243	250	whether
O	251	256	whole
O	257	263	breast
O	264	276	radiotherapy
O	277	279	is
O	280	290	beneficial
O	290	291	.

O	292	299	Between
O	300	307	January
O	308	312	1996
O	313	316	and
O	317	321	June
O	322	326	2004
O	326	327	,
O	328	331	the
B-location	332	340	Austrian
O	341	347	Breast
O	348	351	and
O	352	362	Colorectal
O	363	369	Cancer
O	370	375	Study
O	376	381	Group
O	382	383	(
O	383	388	ABCSG
O	388	389	)
O	390	398	randomly
O	399	407	assigned
B-total-participants	408	411	869
O	412	417	women
O	418	420	to
O	421	428	receive
O	429	435	breast
O	436	448	radiotherapy
O	449	450	+
O	450	451	/
O	451	452	-
O	453	458	boost
O	459	460	(
O	460	461	n
O	462	463	=
B-intervention-participants	464	467	414
O	467	468	)
O	469	471	or
B-control	472	475	not
O	476	477	(
O	477	478	n
O	479	480	=
B-control-participants	481	484	417
O	484	485	)
O	486	491	after
O	492	498	breast
O	498	499	-
O	499	509	conserving
O	510	517	surgery
O	518	519	(
O	519	524	ABCSG
O	525	530	Study
O	531	533	8A
O	533	534	)
O	534	535	.

O	536	545	Favorable
O	546	551	early
O	552	558	breast
O	559	565	cancer
O	566	569	was
O	570	579	specified
O	580	582	as
O	583	588	tumor
O	589	593	size
O	594	595	<
O	595	596	3
O	597	599	cm
O	599	600	,
O	601	608	Grading
O	609	610	1
O	611	613	or
O	614	615	2
O	615	616	,
O	617	625	negative
O	626	631	lymph
O	632	637	nodes
O	637	638	,
O	639	647	positive
O	648	656	estrogen
O	657	660	and
O	660	661	/
O	661	663	or
O	664	676	progesterone
O	677	685	receptor
O	686	692	status
O	692	693	,
O	694	697	and
O	698	708	manageable
O	709	711	by
O	712	718	breast
O	718	719	-
O	719	729	conserving
O	730	737	surgery
O	737	738	.

O	739	745	Breast
O	746	758	radiotherapy
O	759	762	was
O	763	772	performed
O	773	778	after
O	779	789	lumpectomy
O	790	794	with
O	795	796	2
O	797	807	tangential
O	808	815	opposed
O	816	822	breast
O	823	829	fields
O	830	834	with
O	835	839	mean
O	840	842	50
O	843	845	Gy
O	845	846	,
O	847	851	plus
O	852	857	boost
O	858	860	in
O	861	863	71
O	863	864	%
O	865	867	of
O	868	876	patients
O	877	881	with
O	882	886	mean
O	887	889	10
O	890	892	Gy
O	892	893	,
O	894	896	in
O	897	898	a
O	899	905	median
O	906	908	of
O	909	910	6
O	911	916	weeks
O	916	917	.

O	918	921	The
O	922	929	primary
O	930	938	endpoint
O	939	942	was
B-outcome-Measure	943	948	local
I-outcome-Measure	949	956	relapse
I-outcome-Measure	956	957	-
I-outcome-Measure	957	961	free
I-outcome-Measure	962	970	survival
O	970	971	;
O	972	979	further
O	980	989	endpoints
O	990	994	were
B-outcome-Measure	995	1008	contralateral
I-outcome-Measure	1009	1015	breast
I-outcome-Measure	1016	1022	cancer
O	1022	1023	,
B-outcome-Measure	1024	1031	distant
I-outcome-Measure	1032	1042	metastases
O	1042	1043	,
O	1044	1047	and
B-outcome-Measure	1048	1055	disease
I-outcome-Measure	1055	1056	-
I-outcome-Measure	1056	1060	free
I-outcome-Measure	1061	1064	and
I-outcome-Measure	1065	1072	overall
I-outcome-Measure	1073	1081	survival
O	1081	1082	.

O	1083	1086	The
O	1087	1093	median
O	1094	1100	follow
O	1100	1101	-
O	1101	1103	up
O	1104	1107	was
O	1108	1110	53
O	1110	1111	.
O	1111	1112	8
O	1113	1119	months
O	1119	1120	.

O	1121	1124	The
O	1125	1129	mean
O	1130	1133	age
O	1134	1137	was
B-age	1138	1140	66
I-age	1141	1146	years
O	1146	1147	.

O	1148	1155	Overall
O	1155	1156	,
O	1157	1162	there
O	1163	1167	were
O	1168	1170	21
B-outcome	1171	1176	local
I-outcome	1177	1185	relapses
O	1185	1186	,
O	1187	1191	with
B-iv-bin-abs	1192	1193	2
O	1194	1202	relapses
O	1203	1205	in
O	1206	1209	the
O	1210	1222	radiotherapy
O	1223	1228	group
O	1229	1230	(
B-outcome	1230	1231	5
I-outcome	1231	1232	-
I-outcome	1232	1233	y
I-outcome	1234	1238	rate
B-iv-bin-percent	1239	1240	0
I-iv-bin-percent	1240	1241	.
I-iv-bin-percent	1241	1242	4
I-iv-bin-percent	1242	1243	%
O	1243	1244	)
O	1245	1247	vs
O	1247	1248	.
B-control-participants	1249	1251	19
O	1252	1254	in
O	1255	1258	the
O	1259	1261	no
O	1261	1262	-
O	1262	1274	radiotherapy
O	1275	1280	group
O	1281	1282	(
B-cv-bin-percent	1282	1283	5
I-cv-bin-percent	1283	1284	.
I-cv-bin-percent	1284	1285	1
I-cv-bin-percent	1285	1286	%
O	1286	1287	)
O	1287	1288	,
O	1289	1301	respectively
O	1302	1303	(
O	1303	1304	p
O	1305	1306	=
O	1307	1308	0
O	1308	1309	.
O	1309	1313	0001
O	1313	1314	,
O	1315	1321	hazard
O	1322	1327	ratio
O	1328	1330	10
O	1330	1331	.
O	1331	1332	2
O	1332	1333	)
O	1333	1334	.

B-outcome	1335	1342	Overall
I-outcome	1343	1351	relapses
O	1352	1360	occurred
O	1361	1363	in
O	1364	1366	30
O	1367	1375	patients
O	1375	1376	,
O	1377	1381	with
B-iv-bin-abs	1382	1383	7
O	1384	1390	events
O	1391	1393	in
O	1394	1397	the
O	1398	1410	radiotherapy
O	1411	1416	group
O	1417	1418	(
B-outcome	1418	1419	5
I-outcome	1419	1420	-
I-outcome	1420	1421	y
I-outcome	1422	1426	rate
B-iv-bin-percent	1427	1428	2
I-iv-bin-percent	1428	1429	.
I-iv-bin-percent	1429	1430	1
I-iv-bin-percent	1430	1431	%
O	1431	1432	)
O	1433	1435	vs
O	1435	1436	.
B-cv-bin-abs	1437	1439	23
O	1440	1446	events
O	1447	1449	in
O	1450	1453	the
O	1454	1456	no
O	1456	1457	-
O	1457	1469	radiotherapy
O	1470	1475	group
O	1476	1477	(
B-cv-bin-percent	1477	1478	6
I-cv-bin-percent	1478	1479	.
I-cv-bin-percent	1479	1480	1
I-cv-bin-percent	1480	1481	%
O	1481	1482	)
O	1483	1484	(
O	1484	1485	p
O	1486	1487	=
O	1488	1489	0
O	1489	1490	.
O	1490	1493	002
O	1493	1494	,
O	1495	1501	hazard
O	1502	1507	ratio
O	1508	1509	3
O	1509	1510	.
O	1510	1511	5
O	1511	1512	)
O	1512	1513	.

O	1514	1516	No
O	1517	1528	significant
O	1529	1540	differences
O	1541	1545	were
O	1546	1551	found
O	1552	1555	for
B-outcome	1556	1563	distant
I-outcome	1564	1574	metastases
O	1575	1578	and
B-outcome	1579	1586	overall
I-outcome	1587	1595	survival
O	1595	1596	.

O	1597	1603	Breast
O	1604	1616	radiotherapy
O	1617	1618	+
O	1618	1619	/
O	1619	1620	-
O	1621	1626	boost
O	1627	1629	in
O	1630	1635	women
O	1636	1640	with
O	1641	1650	favorable
O	1651	1656	early
O	1657	1663	breast
O	1664	1670	cancer
O	1671	1676	after
O	1677	1687	lumpectomy
O	1688	1696	combined
O	1697	1701	with
O	1702	1711	tamoxifen
O	1711	1712	/
O	1712	1723	anastrazole
O	1724	1729	leads
O	1730	1732	to
O	1733	1734	a
O	1735	1746	significant
O	1747	1756	reduction
O	1757	1759	in
O	1760	1765	local
O	1766	1769	and
O	1770	1777	overall
O	1778	1785	relapse
O	1785	1786	.
